BMS wrote AUGTYRO down by 1.4 billion dollars. The charge is not the loss, it is the accounting noticing the loss. The same broken forecast lands as an intangible impairment on the acquirer, a provision for changes in expected cash flows on the royalty investor, and nothing at all

A regional out-licence usually ends by running off or by reverting on termination. A third ending is the boomerang: the licensor, often after being acquired itself, buys the territory back for fresh cash and extinguishes the royalty.

On 16 July 2026 Kalshi began listing clinical-trial and FDA contracts. Every royalty, milestone and CVR already embedded a probability of success. Now a handful of those numbers trade in the open. Here is what each contract prices, who is allowed to know it, and whether any of it is hedgeable.

The week in numbers Six days, July 12 to 17 of W29. The headline is Lilly's roughly $2.8B (up to $3.8B with CVRs) acquisition of AtaiBeckley for its psychedelic depression pipeline, announced July 16. The largest prints are completions, not originations: GSK / Nuvalent ($10.6B), Angelini

A drug-discovery company that out-licenses an asset to a larger partner ends up holding two very different things. One is a royalty on the partner's future sales, a contractual cash flow with a defined lifespan. The other is the rest of the pipeline, a set of

The Michael J. Fox Foundation for Parkinson's Research (MJFF) is the largest nonprofit funder of Parkinson's research in the world, and, unusually for this series, it files a full public tax return. It is donor-funded, evergreen, and structured as a grantmaker rather than an investor.

Vera Therapeutics spent six years turning a drug that had failed in lupus, MS, and arthritis into an approved kidney medicine. On 7 July 2026 the FDA cleared atacicept, and in the same moment flipped a dormant royalty owed to Merck KGaA into a live, cash-paying obligation. Vera is

A royalty monetisation is characterised separately by tax law, accounting, bankruptcy law, and its commercial terms. The four answers can differ on the same deal. Only the tax answer decides whether the upfront cash is income this year or deferred across the life of the stream. This piece covers how

The development funding bond is a royalty deal that was never a royalty: fixed multiple, fixed schedule, guaranteed by the parent, paid regardless of sales. Why both sides chose debt over a true sale, the tax and accounting logic, and why the structure stays a category of two.